Stock Analysis
- United States
- /
- Medical Equipment
- /
- NasdaqCM:AVGR
Avinger Full Year 2022 Earnings: US$4.36 loss per share (vs US$4.57 loss in FY 2021)
Avinger (NASDAQ:AVGR) Full Year 2022 Results
Key Financial Results
- Revenue: US$8.27m (down 18% from FY 2021).
- Net loss: US$27.2m (loss widened by 26% from FY 2021).
- US$4.36 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Avinger shares are down 5.8% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 3 warning signs for Avinger that you should be aware of.
What are the risks and opportunities for Avinger?
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally.
Risks
Has less than 1 year of cash runway
Shareholders have been substantially diluted in the past year
Does not have a meaningful market cap ($7M)
Further research on
Avinger
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.